CDMO

Bio & Pharma Lotte Biologics eyes first ADC CDMO order in 2025

SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...

Bio & Pharma Celltrion BioSolutions launched to venture into CDMO

Celltrion Inc. on Tuesday launched its contract development and manufacturing organization unit Celltrion BioSolutions Co. in its foray into the CDM...

Bio & Pharma Boryung, Lotus Pharma signs CDMO deal on anticancer injection

South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...

Bio & Pharma SK Pharmteco bags obesity treatment deal worth up to $1.4 bn

SK Pharmteco Co., a contract development and manufacturing organization (CDMO), has secured an obesity treatment order worth up to 2 trillion won ($...

Bio & Pharma Celltrion to break ground on CDMO plant in 2025: Chairman Seo

South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...

Bio & Pharma Samsung Biologics wins $668 million CDMO deal with European pharma

Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...

Bio & Pharma Celltrion to establish CDMO subsidiary

Celltrion Inc., South Korea’s largest biosimilar maker, said on Friday it plans to establish a contract development and manufacturing organiza...

Bio & Pharma Celltrion earmarks billions of dollars to build CDMO plant: chairman

Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...

Bio & Pharma Celltrion chairman announces venture into CDMO market

South Korea’s biosimilar maker Celltrion Inc. will venture into the contract development and manufacturing organization (CDMO) market, the com...

Bio & Pharma Lotte to restructure bio business to focus on CDMO

South Korea’s retail-to-chemical conglomerate Lotte Group will restructure its bio business to focus on the profit-making medicine bio develop...

Corporate restructuring SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk

SK Inc., the holding and investment company of SK Group, South Korea’s second-largest conglomerate, is negotiating to sell a major asset of it...

Bio & Pharma Samsung Biologics eyes windfall gain amid US-China row

SAN DIEGO – Samsung Biologics Co. is enjoying a stream of contract development and manufacturing order inquiries from big pharmaceutical compa...

Bio & Pharma S.Korea’s GC Cell targets global cell therapy CDMO business

GC Cell Corp., an affiliate of South Korea’s major pharmaceutical company GC Biopharma Corp., is targeting the cell therapy contract developme...

Bio & Pharma SK Pharmteco launches new viral vector platforms, key for CGT

SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two...

Bio & Pharma South Korean bio, pharma industry set to take leap

South Korea’s chemical maker LG Chem Ltd. is expected to reap more than 1 trillion won ($768.5 million) in sales this year from its new growth...

Bio & Pharma Lotte Biologics to break ground on 1st local CDMO plant in 2024

South Korea’s Lotte Biologics Co. is set to start building its first local facility for drug manufacturing next year, aiming for 400,000 liter...

Bio & Pharma Prestige Biologics partners with Indian company for CDMO

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, is expanding its CDMO b...

Mergers & Acquisitions IMM PE invites potential buyers for Genuone worth $752 mn

South Korea’s top-tier contract drugmaker Genuone Sciences Inc. with an estimated value of up to 1 trillion won ($752 million) is smooth saili...

Bio & Pharma SK Pharmteco gears up for big leap in advanced biotherapies

SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), is upping the ante in its b...

Bio & Pharma SK Bioscience buys 6.5 million Novavax shares for $83.4 million

SK Bioscience Co., the drug-making unit of South Korea’s SK Group, said on Wednesday it has signed a deal to buy 6.5 million shares in US vacc...

Bio & Pharma SK Pharmteco secures 12 global pharma clients, sets up US R&D center

SK Pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has secured 12 global pharm...

Bio & Pharma Samsung Biologics, Pfizer sign $411.3 mn agreement for long-term CDMO

Samsung Biologics Co., the world’s No. 1 contract drugmaker, announced a groundbreaking strategic partnership with Pfizer on Thursday, marking...

Bio & Pharma Samsung Biologics to double production by 2032; eyes ADCs, M&As

BOSTON – Samsung Biologics Co., the world’s No. 1 contract drugmaker, plans to more than double its total annual production capacity to ...

Bio & Pharma BIO USA 2023 to draw S.Korean biotech leaders, startups

More than 500 South Korean companies from top business groups to AI-based biotech startups are slated to attend the Bio International Convention 202...

Pre-IPOs SK Pharmteco again seeks $382 mn in pre-IPO funding

SK Pharmteco Co., a contract development and manufacturing organization (CDMO), is eyeing pre-initial public offering funding again after it dropped...

Bio & Pharma Samsung Biologics to invest $1.5 bn for 5th CDMO factory

Samsung Biologics Co. is slated to inject 2 trillion won ($1.5 billion) to build its fifth plant in South Korea. It will be a fast follow-up investm...

Bio & Pharma S.Korea's Prestige Biologics attracts $59 mn overseas investment

Prestige Biologics Co., a South Korean biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Tuesday th...

Bio & Pharma Daewoong accelerates investment in CDMO business

Daewoong, the holding company of South Korea's pharmaceutical-oriented Daewoong Group, is speeding up its pace to beef up its contract development a...

Bio & Pharma Medipost, OmniaBio to enhance cooperation for CDMO business

South Korea's stem-cell therapy company Medipost announced on Thursday that its Canadian affiliate OmniaBio made a two-day visit to South Korea on N...

Bio & Pharma Samsung Biologics in CDO deal talks with global pharma firm

FRANKFURT – Samsung Biologics Co., the world’s largest contract drugmaker, is in talks to develop medicines for a global pharmaceutical ...